Study finds that Rousselot collagen supports bone health

Study finds that Rousselot collagen supports bone health

Research published in Osteoporosis International reports on the benefits of Peptan on bone health.

The latest Rousselot study conducted at AgroParisTech, Nutrition Physiology and Ingestive Behavior laboratory under Pr. Daniel Tomé's supervision and published in September 2011 in Osteoporosis International has confirmed the benefits of Peptan™ on bone health.

Osteoporosis is a critical disorder characterized by bone loss and an increased risk of fracture. It results from an imbalance between bone formation and bone resorption occurring mainly, although not only, in post-menopausal women as a consequence of estrogen deficiency that in turn increases osteoclast activity.

In response to consumer concerns about long-term bone health, for several years Rousselot has been carrying out studies to demonstrate that an oral intake of Peptan™ may have a positive impact in preserving Bone Mineral Density (BMD) before osteoporosis appears.

The aim of the latest study was to evaluate the effect of Peptan™ hydrolyzed collagen on the bone health of ovariectomized mice (OVX) of different ages. Animals were divided into different groups: some groups of mice ingested Peptan™ after OVX; another group of mice ingested Peptan™ several weeks before OVX and continued over additional weeks; another ingested Raloxifene - a drug commonly indicated for osteoporosis - instead of hydrolyzed collagen.

Twenty-six weeks after the OVX procedure, Peptan™ hydrolyzed collagen ingestion was able to significantly improve BMD and some femur biomechanical parameters. Moreover, hydrolyzed collagen ingestion for one month before surgery prevented a BMD decrease. The third major finding was that Peptan™ hydrolyzed collagen could prevent a BMD decrease as efficiently as Raloxifene.

In conclusion, the study confirmed once more the importance of Peptan™ as a nutritional complement to prevent bone loss, and to restore bone mineral density.

More information will be available at Rousselot’s stand (42H51) at CPHI 2011, Frankfurt.

The complete article is available on

About Rousselot®:Part of VION N.V. (N.L.), Rousselot® is the leading manufacturer of gelatine and collagen peptides to the food, pharmaceutical and technical industries. With a staff of 2,400 people, the company benefits from a global sales and production network of 12 plants and 10 sales offices located in Europe, North America, South America and Asia.

VION N.V.:VION N.V. is an internationally operating food group that produces high-quality foods and ingredients for humans and animals. The company consists of two internationally operating divisions: VION Ingredients, and VION Food. VION has an annual turnover of more than € 9 billion and provides employment for 27,000 people worldwide. The VION head office is in Son, the Netherlands.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.